NEW YORK – Molecular diagnostics company BioNexus Gene Lab Corp. (BGLC) on Thursday said it has signed a memorandum of understanding with Shenzhen Rongguang Health Group, a healthcare services provider in China, to develop new healthcare technologies and processes facilitating precision medicine and make them accessible in underserved markets in Asia.
Kuala Lumpur, Malaysia-based BGLC's MRNA Scientific subsidiary will work with Shenzhen Rongguang Health Group to advance technologies for early cancer screening, preventive healthcare, and precision medicine, including a focus on regenerative medicine and chronic disease management.
As part of the collaboration, MRNA Scientific will lead an effort to improve cancer screening in Southeast Asia and China with genomic testing and molecular diagnostics. Together, the companies also will explore opportunities to improve preventive healthcare and chronic disease management by developing personalized healthcare plans based on advanced diagnostics.
In addition, the firms will work together on R&D in regenerative medicine and noncellular exosome therapy, in which they see potential for anti-aging and chronic disease therapies.
"This partnership marks a pivotal moment for BGLC and our subsidiary, MRNA Scientific," BGLC CEO Sam Tan said in a statement. "By joining forces with Shenzhen Rongguang Health Group, we are not only advancing our efforts in cancer screening but also expanding into the broader healthcare sector."